Key takeaways
- 31% reduction in moderate/severe exacerbations with dupilumab add-on vs placebo in eosinophilic COPD on triple therapy (pooled BOREAS+NOTUS, IRR 0.687; Lancet Respir Med 2025, PMID 39900091)
- 41% reduction in exacerbation rate with ensifentrine vs placebo (pooled ENHANCE-1/2, rate ratio 0.59; Chest 2024, PMID 39197510)
- 25% fewer moderate/severe exacerbations with FF/UMEC/VI triple vs LAMA/LABA dual — the incumbent benchmark (IMPACT, RR 0.75; NEJM 2018, PMID 29668352)
Two 2024 launches ended a decade of inhaler-only competition — but each treats a different slice of the triple-therapy failure population
Through 2023 the US COPD maintenance market was a two-horse inhaler race: GSK's Trelegy Ellipta and AstraZeneca's Breztri Aerosphere, both single-inhaler ICS/LAMA/LABA triples competing on exacerbation and mortality data (IMPACT and ETHOS). The strategic question was device, dosing, and formulary tier — not mechanism. That question is now obsolete for the patients who still exacerbate on triple therapy.
In mid-2024 the FDA approved ensifentrine (Ohtuvayre), the first novel inhaled mechanism in COPD in more than twenty years, and dupilumab (Dupixent), the first biologic ever approved in COPD. They do not compete head-to-head: ensifentrine is a non-steroidal add-on usable at any step, while dupilumab is gated to the roughly type-2/eosinophilic endotype on maximal triple therapy. The commercial contest is now about which failure phenotype a payer will pay to treat, and with what.
Six regimens define the US COPD maintenance market: two incumbent triples, two 2024 first-in-class add-ons, one oral PDE4, one dual-bronchodilator base
| Brand (INN) | Class / mechanism | Company | US approval | Key trial — result | Positioning |
|---|---|---|---|---|---|
| Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol) | ICS/LAMA/LABA single-inhaler triple, once-daily | GSK | 2017 (COPD) | IMPACT — 25% fewer mod/severe exacerbations vs LAMA/LABA (RR 0.75); PMID 29668352 | Once-daily triple anchor; broad exacerbation-history use, market leader |
| Breztri Aerosphere (budesonide / glycopyrrolate / formoterol) | ICS/LAMA/LABA triple (metered-dose), twice-daily | AstraZeneca | 2020 | ETHOS — all-cause mortality signal + CV/cardiopulmonary benefit vs LAMA/LABA; PMID 39213002 | Twice-daily MDI triple; mortality and cardiovascular-safety narrative |
| Dupixent (dupilumab) | IL-4R-alpha monoclonal antibody, anti-type-2 biologic (add-on, SC) | Sanofi / Regeneron | 2024 (Sept) | BOREAS + NOTUS — 31% fewer exacerbations (IRR 0.687); PMIDs 37272521, 38767614, 39900091 | First biologic in COPD; add-on for eosinophils >=300 on triple therapy |
| Ohtuvayre (ensifentrine) | Inhaled dual PDE3/PDE4 inhibitor, non-steroidal (nebulized) | Verona Pharma (acquired by Merck, 2025) | 2024 (June) | ENHANCE-1/2 — 41% fewer exacerbations pooled (RR 0.59) + FEV1 gain; PMIDs 37364283, 39197510 | First novel inhaled mechanism in COPD in 20+ years; add at any step, phenotype-agnostic |
| Daliresp / roflumilast (generic) | Oral PDE4 inhibitor | Generic (orig. AstraZeneca) | 2011 | REACT — ~14% fewer exacerbations added to ICS/LABA; PMID 25684586 | Oral add-on for severe chronic-bronchitis exacerbators; tolerability-limited uptake |
| LAMA/LABA duals (e.g., Anoro, Stiolto) | Dual long-acting bronchodilator, no steroid | GSK / Boehringer Ingelheim | 2013-2015 | Foundation maintenance; ICS/add-on layered by eosinophils + exacerbation history | Step-up base of the pathway; the denominator every add-on sits on top of |
Sources: IMPACT: NEJM 2018, PMID 29668352, doi:10.1056/NEJMoa1713901. ETHOS CV/mortality analysis: AJRCCM 2025, PMID 39213002, doi:10.1164/rccm.202312-2311OC. BOREAS: NEJM 2023, PMID 37272521. NOTUS: NEJM 2024, PMID 38767614. Pooled dupilumab: Lancet Respir Med 2025, PMID 39900091, doi:10.1016/S2213-2600(24)00409-0. ENHANCE trials: AJRCCM 2023, PMID 37364283; pooled exacerbation analysis Chest 2024, PMID 39197510, doi:10.1016/j.chest.2024.07.168. REACT: Lancet 2015, PMID 25684586, doi:10.1016/S0140-6736(14)62410-7. Approvals and sponsors: FDA Drugs@FDA (NDA209482 Trelegy; NDA212122 Breztri; NDA217389 Ohtuvayre; Dupixent BLA label). All PMIDs verified live via PubMed.
What this brief answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- Which patients actually convert to the two new add-ons — and how large is each addressable pool on top of triple therapy? • Endotype segmentation: eosinophil-gated (dupilumab, eos >=300) vs mechanism-agnostic (ensifentrine), with the triple-therapy-failure denominator each competes for
- Does dupilumab's biologic profile displace ensifentrine, or do they stack on the same exacerbator? • A sequencing map showing where the two 2024 entrants overlap, where they are additive, and where roflumilast still holds the oral-add-on niche
- How defensible are the incumbent triples once the exacerbation conversation shifts to biology? • A read on GSK/AstraZeneca positioning, mortality and CV narratives (ETHOS) vs the add-on tier, and the reformulation/device levers left to them
What's inside
-
1 · The Two-Tier Market: Inhaler Triples vs. the Biology-Defined Add-On Tier 4 pp
- How Trelegy Ellipta and Breztri Aerosphere's single-inhaler triple competition (IMPACT, ETHOS) has been overtaken by a biology-defined add-on tier
- Why ensifentrine and dupilumab, both approved in 2024, target patients who still exacerbate despite maximal triple therapy
-
2 · Six Regimens, Six Mechanisms: From Single-Inhaler Triples to the First COPD Biologic 8 pp
- Full drug profiles spanning Trelegy, Breztri, Dupixent, Ohtuvayre, generic roflumilast, and LAMA/LABA duals
- Why dupilumab (2024) is the first-ever COPD biologic and ensifentrine the first novel inhaled mechanism in over twenty years
-
3 · IMPACT, ETHOS, ENHANCE, BOREAS/NOTUS: The Exacerbation-Reduction Evidence Head-to-Head 4 pp
- The pivotal-trial exacerbation reductions: 25% for Trelegy (IMPACT), 41% for ensifentrine (pooled ENHANCE), and 31% for dupilumab (pooled BOREAS+NOTUS)
- How ETHOS's mortality and cardiopulmonary-benefit signal differentiates Breztri from the IMPACT-based triple benchmark
-
4 · The Eosinophil Gate: How Payers Route Access to Dupilumab and Ensifentrine 5 pp
- Why dupilumab is gated to the roughly type-2/eosinophilic endotype (eos >=300) on maximal triple therapy, while ensifentrine is phenotype-agnostic
- How the eosinophil-count threshold determines which failure phenotype a payer will pay to treat, and with what
-
5 · What Comes After Ensifentrine and Dupilumab: The Next-Generation COPD Pipeline 4 pp
- The pipeline landscape building on the eosinophil-gated and mechanism-agnostic precedents set by dupilumab and ensifentrine
- Where roflumilast's oral add-on niche still holds against the two 2024 entrants
-
6 · Can GSK and AstraZeneca Defend the Triple-Therapy Base as the Conversation Shifts to Biology? 3 pp
- GSK and AstraZeneca's positioning options, including ETHOS's mortality and CV narratives, against the new add-on tier
- The reformulation and device levers left to the incumbent triples as biology reshapes the conversation
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom brief delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this brief
AXLRx delivers US COPD competitive intelligence built for pharma and biotech commercial, access, and medical affairs teams. Custom brief in 72 hours.
- 1. Submit your requestUse the intake form to specify your indication, geography, and commercial question.
- 2. Scoping callAXLRx analyst confirms scope, comparators, and delivery format.
- 3. DeliveryResearch-verified brief in 72 hours with optional analyst readout.
How AXLRx builds this brief
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
Every AXLRx brief is built from primary regulatory sources (FDA, ClinicalTrials.gov), peer-reviewed literature, and live payer policy documentation — not secondary summaries. No secondary summaries, market research reports, or unverified estimates are used. Findings are independently verified before inclusion.
US COPD Competitive Intelligence sources: FDA Drugs@FDA (approvals and labels), primary trial publications, ClinicalTrials.gov, and live payer/HTA policy documentation.
- Every trial citation verified against the source publication; the returned title matches the trial cited in each case.
- FDA approvals confirmed via Drugs@FDA: Ohtuvayre/ensifentrine approved 26 Jun 2024 (NDA217389, now sponsored by MSD after Merck's 2025 acquisition of Verona Pharma); Breztri NDA212122 (AstraZeneca); Trelegy NDA209482 (GSK).
- Dupixent COPD indication confirmed on the current FDA label (IL-4-receptor-alpha antagonist, Sanofi-Aventis); COPD add-on approval Sept 2024.
Frequently asked questions
Deliverables What formats are included with every brief?
Every commissioned brief includes three deliverables: a 20–30 page PDF analyst brief with verified sources and exhibit tables, an editable Excel model (drug comparison grid, payer formulary data, or patient flow model — depending on deliverable type), and a 10–15 slide PowerPoint readout deck formatted for commercial team presentations. An optional 60-minute analyst readout call is included with all deliveries.
Sources What sources does AXLRx use, and how are findings verified?
AXLRx builds from primary sources only: FDA Drugs@FDA approval records and labels, the primary trial publications for the recently approved inhaled and biologic agents, ClinicalTrials.gov registrations, and live commercial payer coverage policy. No secondary summaries or market research reports. Every factual claim is independently verified before inclusion. Source citations are provided for all key data points in the delivered brief.
Customisation Can I tailor the brief to my specific question, geography, or comparator set?
Yes. The intake form captures your indication, target geography, key comparator drugs, and the specific commercial question you need answered. A scoping call confirms scope before research starts. Custom extensions (additional payer markets, pipeline agent profiles, or country-specific deep-dives) can be added to any standard brief. Commission via the intake form to start.